ZyVersa’s cholesterol efflux mediator gains patent in Europe
Phase 2
Preview
Source: Pharmaceutical Technology
VAR 200 is claimed to eliminate accumulated lipids from the kidney. Credit: Robina Weermeijer on Unsplash.
ZyVersa Therapeutics has received a patent from the European Patent Office for its VAR 200 (2-hydroxypropyl-beta-cyclodextrin) to treat patients with diabetic nephropathy/diabetic kidney disease.
Developed in the laboratories of the University of Miami in the US, VAR 200 is a cholesterol efflux mediator that is claimed to eliminate accumulated lipids from the kidney.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Naltrexone La in Opium (Opioid) Addiction GlobalData
Preview
Source: Pharmaceutical Technology
View allCompanies IntelligenceZyVersa Therapeutics IncL&F Research LLCLAMP, INC.View all
It is currently in its Phase IIa development stage.
This asset is being evaluated to cut down the build-up of renal cholesterol and lipid that harms the filtration system of kidneys in individuals with glomerular diseases such as focal segmental glomerulosclerosis, diabetic kidney disease and Alport syndrome.
ZyVersa received a global licence to develop and market VAR 200 from L&F Research.
In June 2023, the European Patent Office issued a notice of intention to grant a patent for VAR 200.
ZyVersa Therapeutics co-founder, chairman, CEO and president Stephen Glover stated: “Approval of this patent claiming our cholesterol efflux mediator VAR 200 for use in treating diabetic kidney disease speaks to the innovative and important research conducted by Dr Fornoni and her team involving removal of excess cholesterol and lipids that damage the kidneys’ filtration system.
“Strengthening our intellectual property portfolio for VAR 200 and expanding our patent protection and exclusive rights into additional geographic regions will further enable ZyVersa to increase shareholder value as VAR 200 advances into clinical trials, which are planned for initiation in the fourth quarter of this year.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.